Case-based debate: is there evidence for local treatment in oligometastatic prostate cancer?
What can histology tell us to ProtecT against prostate cancer?
Biosimilars are alternatives for original antibodies
Promising avenues for whole genome sequencing
Wim van Harten
Biosimilars and the exciting results of the REFLECTIONS trial